| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MRC2 |
| Uniprot No | Q9UBG0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 105-214aa |
| 氨基酸序列 | ASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTR SGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTST GREDGHLWCA |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MRC2(Endo180/CD280)重组蛋白的3篇示例文献摘要，供参考：
---
1. **文献名称**：*Recombinant expression and functional characterization of the human MRC2 protein in mammalian cells*
**作者**：Smith A, et al.
**摘要**：本研究成功在HEK293细胞中表达了功能性人源MRC2重组蛋白，验证了其与胶原蛋白的特异性结合能力，并证实其在细胞迁移实验中的促进作用，为肿瘤侵袭机制研究提供了工具。
---
2. **文献名称**：*Structural analysis of the MRC2 ectodomain reveals a unique collagen-binding mechanism*
**作者**：Jones R, et al.
**摘要**：通过昆虫细胞表达系统获得高纯度MRC2胞外域重组蛋白，结合X射线晶体学解析其三维结构，揭示了其与胶原纤维结合的独特结构域，阐明了其在组织重塑中的分子机制。
---
3. **文献名称**：*Development of a MRC2-targeted recombinant protein for antifibrotic therapy*
**作者**：Chen L, et al.
**摘要**：构建了携带MRC2受体结合域的重组融合蛋白，在肺纤维化小鼠模型中证实其通过竞争性抑制胶原摄取减轻纤维化病变，展示了MRC2重组蛋白的治疗潜力。
---
注：以上为模拟示例，实际文献需通过PubMed(https://pubmed.ncbi.nlm.nih.gov)或Web of Science检索关键词"MRC2 recombinant"、"Endo180 expression"获取。
**Background of MRC2 Recombinant Protein**
MRC2 (Mannose Receptor C-Type 2), also known as Endo180 or CD280. is a transmembrane glycoprotein belonging to the mannose receptor family. It plays a critical role in extracellular matrix (ECM) remodeling by mediating endocytosis of collagen and other glycoproteins. Structurally, MRC2 contains an N-terminal cysteine-rich domain, a fibronectin type II domain, multiple C-type lectin-like domains, and a cytoplasmic tail with signaling motifs. These domains enable its interaction with collagen, glycosylated ligands, and intracellular trafficking machinery.
MRC2 is highly expressed in fibroblasts, macrophages, and certain cancer cells, where it facilitates cell migration, tissue repair, and ECM turnover. Dysregulation of MRC2 is linked to pathological processes such as fibrosis, tumor progression, and metastasis. In cancer, MRC2 promotes invasive behavior by enhancing collagen internalization and modulating the tumor microenvironment.
Recombinant MRC2 protein is engineered using expression systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications. It is often produced as a soluble extracellular domain or tagged fusion protein for functional studies. This recombinant tool enables researchers to investigate MRC2’s ligand-binding properties, signaling pathways, and role in diseases. Applications include studying ECM dynamics, screening therapeutic agents targeting MRC2-collagen interactions, and exploring its potential as a biomarker in cancer or fibrotic disorders. Its versatility makes it valuable for both basic research and drug development.
×
